Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (38)	6/3/2002 1:08:04 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 684

IMGN is currently trading for about a dime over book value. It has the potential, IMHO, to double or more on any kind of positive news, which should be coming. By the end of this year, two drugs that are currently in trials should complete Phase I and enter Phase II. Three of it's partners, DNA, MLNM and BI, should bring drugs into the clinic. Most of these events will bring is substantial milestone payments to IMGN. The stock has fallen from a high of $45 to under $4, it certainly is oversold. Gary